IL2 and neoplasm: With fully pegylated IL-2 hardly showing biological activity, the partial pegylation and slow release of PEG chains, as demonstrated in vivo, leads to the formation of IL-2 conjugates, selectively stimulating CD8+ T cells, CD4+ T cells, and natural killer cells without increasing regulatory T cells within the tumor microenvironment [87].